RxDoctor Payments Data

Tejaswi Voladri, MD

Family Medicine · Weirton, WVNPI 1093261349

Payments from drug & device makers

$1,180in general payments, 2019–2025

Across 36 payments — averaging $32.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$194
  • Shockwave Medical, Inc$168
  • Medtronic$155
  • Novo Nordisk$122
  • AstraZeneca$121
  • GSK$115
  • plus $304 from 8 others

What the payments were for

  • Food & beverage$1,180100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,180 in reported general payments places this provider in the 70th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$87,164
Medicare patients
251
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate51$42,645
OzempicSemaglutide37$34,411
EliquisApixaban41$31,355
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$28,858
XareltoRivaroxaban20$25,637
MounjaroTirzepatide15$15,294
JardianceEmpagliflozin15$15,020
RybelsusSemaglutide15$13,983
LinzessLinaclotide14$12,599
Invokamet XrCanagliflozin/Metformin Hcl12$6,755
Combivent RespimatIpratropium/Albuterol Sulfate13$6,279
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,406
SymbicortBudesonide/Formoterol Fumarate11$3,256
Albuterol Sulfate HfaAlbuterol Sulfate70$1,903
Levothyroxine Sodium203$1,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$122$48,39452 claims
GSKTrelegy Ellipta$115$28,85844 claims
Johnson & JohnsonXarelto$42$25,63720 claims
Boehringer IngelheimJardiance, Combivent Respimat$58$21,29928 claims
Lilly USA, LLCMounjaro$41$15,29415 claims
AstraZenecaSymbicort$121$3,25611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Weirton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →